Tykerb not effective in treatment of prostate cancer
Tuesday, January 19th, 2010 Posted in prostate cancer | No Comments »According to a recently published report, lapatinib (Tykerb/GlaxoSmithKline) appears to have very limited clinical activity in prostate cancer The research team have published data from a multicenter, Phase II clinical trial of lapatinib in 23 patients with early stage, recurrent, but ...
Association between antibiotic use and risk of prostate cancer
Monday, January 18th, 2010 Posted in prostate cancer | No Comments »A recent study at King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia aimed to assess the association between antibiotics use and risk of prostate cancer. the study team carried out a population-based case-control study using data from Saskatchewan ...
Race, weight may influence success of prostate surgery
Sunday, January 17th, 2010 Posted in prostatectomy | No Comments »A new study at the Duke Prostate Center at Duke University reveals that race and obesity may affect the outcome of men with diabetes who have prostate cancer surgery. The sudy finds among diabetic men undergoing prostatectomy, obese whites have worse ...
New drugs in metastatic castration-resistant prostate cancer
Saturday, January 16th, 2010 Posted in hormone therapy | No Comments »Despite that greater knowledge of prostate cancer biology has led to the isolation of many new and promising targets, treatment of metastatic prostate cancer is still challenging. According to a new review at Institut Gustave-Roussy,Villejuif, France. new agents targeting these molecules ...
Is radical prostatectomy the standard for localized prostate cancer?
Friday, January 15th, 2010 Posted in prostatectomy, radiation therapy | No Comments »A new study at University of Florida aims to review the pertinent literature and compare the outcomes after radical prostatectomy (RP) and radiotherapy (RT). Experts agree tha the probability of cure is similar after either RP or RT, but the likelihood ...
The ned of other biomarkers for detecting prostate cancer
Thursday, January 14th, 2010 Posted in prostate cancer diagnosis | No Comments »Prostate-specific antigen (PSA) has been used for prostate cancer detection since 1994. Although PSA is the best cancer biomarker available, it is not perfect. Many urologists claim PSA lacks both the sensitivity and specificity to accurately detect the presence of ...
Concern over prostate cancer PSA test
Wednesday, January 13th, 2010 Posted in prostate cancer | No Comments »A major European trial has shown, ane in eight men screened for prostate cancer will test positive when they do not have the disease. Early data from the European Randomised Study of Screening for Prostate Cancer, which is being conducted ...
New evaluation of patients eligible for active surveillance protocols
Tuesday, January 12th, 2010 Posted in Uncategorized | No Comments »A recent study at CHU Henri Mondor, Créteil, France, has compared the pathological findings and prostate specific antigen outcome after radical prostatectomy in men eligible for active surveillance according to 3 biopsy inclusion criteria. The team has added to the data ...
Aspirin combined with hormone can shorten lives of prostate cancer patients
Monday, January 11th, 2010 Posted in hormone therapy, prostate cancer risks | No Comments »A new research at Brigham & Women's Hospital and the Dana-Farber Cancer Institute, both in Boston, suggests that men undergoing hormone therapy for prostate cancer who take baby aspirin to protect their heart run a significantly higher risk of dying. Hormonal ...
Re-validation of prostate cancer risk calculator in contemporary patients
Sunday, January 10th, 2010 Posted in prostate cancer risks | No Comments »Statistical models such as the Prostate Cancer Prevention Trial risk calculator have been developed to estimate the cancer risk in an individual and help determine indications for biopsy. It should be remembered that the current calculator was developed using data ...